Kazia Therapeutics - Cantrixil efficacy data presented at AACR
Kazia Therapeutics presented encouraging data from the Cantrixil Phase I study in a poster at American Association for Cancer Research (AACR) this week. Five of the nine evaluable patients (56%) showed stable disease at the completion of monotherapy treatment and one patient achieved an ongoing partial response to Cantrixil plus paclitaxel therapy. The extension cohort has already recruited nine of 12 subjects; data likely H219. Kazia’s primary focus is on GDC-0084, which is in three clinical studies in brain cancers. Initial data from the Phase IIa study in glioblastoma are expected in Q219. We increase our valuation range to between A$84m and A$146m.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.